皮下免疫治疗对儿童变应性鼻炎患者血清人β防御素-2的影响观察  

Effect of subcutaneous immunotherapy on serum levels of human beta defensin-2 in children with allergic rhinitis

作　　者：郑博[1] 王淼[1] 曾毅[1] 刘凡理[1] 叶余丰[1] 项松洁[1] 凡启军[1] 叶建晓[1] 倪丽艳[1] ZHENG Bo WANG Miao ZENG Yi LIU Fanli YE Yufeng XIANG Songjie FAN Qijun YE Jianxiao NI Liyan(Department of Otolaryngology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, Chin)

机构地区：[1]温州医科大学附属第二医院耳鼻咽喉科,浙江温州325000

出　　处：《中国耳鼻咽喉头颈外科》2016年第10期565-568,共4页Chinese Archives of Otolaryngology-Head and Neck Surgery

基　　金：温州市科技局面上项目(Y20130193);国家卫生计生委国家临床重点专科(儿童呼吸专业)开放课题(20130105)联合资助

摘　　要：目的探讨皮下免疫治疗(subcutaneous immunotherapy,SCIT)对变应性鼻炎儿童血清人β防御素-2(human beta defensin-2,HBD-2)的影响。方法 30例行SCIT的变应性鼻炎患儿入治疗组,20例健康儿童入对照组,检测对照组及治疗组治疗前、治疗后半年、1年血清HBD-2浓度,并记录鼻部症状总评分(total nasal symptom scores,TNSS)及药物评分。结果对照组、治疗组治疗前、治疗后半年、1年血清HBD-2浓度为4.62[4.08;4.87]、3.74[3.37;4.61]、4.62[4.13;5.54]、4.79[4.45;6.19]ng/ml,随着SCIT进行,HBD-2浓度逐渐上升(P<0.01)。治疗组治疗前、治疗后半年、1年TNSS分别为7.43±2.15、4.17±2.16、4.20±1.92,药物评分分别为1.25[0.75;1.38]、0.25[0;0.75]、0.25[0;0.75]。治疗组各时间点HBD-2浓度与TNSS及药物评分无明显相关(P均>0.05)。结论变应性鼻炎患者血清HBD-2浓度较正常人低,SCIT可上调变应性鼻炎患者血清HBD-2水平。OBJECTIVE To investigate the effect of＆amp;nbsp;subcutaneousimmunotherapy（SCIT） on levels of the serum human beta defensin-2 in children with allergic rhinitis. METHODS 30 cases of children with allergic rhinitis who were treated by SIT were selected as the treatment group, 20 cases of healthy children as the control group. Serum HBD-2 concentration of the control group was tested. Serum HBD-2 concentration of the treatment group was tested at three different time points： before SCIT, half a year after SCIT and one year after SCIT. And total nasal symptom scores（TNSS） and medication scores were recorded at each time point. RESULTS The serum HBD-2 concentration of the control group, that of the treatment group before SIT, half a year after SIT and one year after SIT were 4.62[4.08; 4.87], 3.74[3.37; 4.61], 4.62[4.13; 5.54], 4.79[4.45;6.19]ng/ml. The HBD-2 concentration gradually increased after SCIT. The TNSS of the treatment group before SCIT, half a year after SCIT and one year after SCIT were 7.43±2.15, 4.17±2.16, 4.20±1.92, The medication scores of the treatment group before SCIT, half a year after SCIT and one year after SCIT were 1.25[0.75; 1.38], 0.25[0; 0.75, 0.25[0; 0.75].There was no correlation （all P〉0.05） between the serum HBD-2 concentration and TNSS or medication scores of the treatment group. CONCLUSION The serum levels of HBD-2 in patients with allergic rhinitis were lower than those in normal persons. The specific immunotherapy raised the serum HBD-2 levels of allergic rhinitis patients.

关 键 词：鼻炎 变应性 常年性 鼻炎 变应性 季节性 Β防御素 脱敏法 免疫 儿童 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]